ABNOM
☆ En los resultados de 2022 del Stiftung Warentest de Alemania, la satisfacción del consumidor con ModelDerm fue sólo ligeramente inferior que con las consultas de telemedicina pagadas.
References
Se sabe que el Q-switched Nd:YAG láser trata eficazmente el nevo de Ota y afecciones similares. Realizamos un estudio para ver qué tan bien funcionaba un láser high-fluence 1064 nm Q-switched Nd:YAG en manchas de Mongolia en áreas inusuales, sin aclarar la piel. Estudiamos 61 pacientes con estas manchas, examinando un total de 70 lesiones. La mitad de las lesiones se trataron con láser, mientras que otras no se trataron para comparar. Evaluamos los resultados utilizando una báscula y un dispositivo llamado Mexameter® para medir los niveles de melanina. Los pacientes fueron seguidos durante un promedio de 14 meses en el grupo de tratamiento y 18 meses en el grupo de observación. Al final del estudio, encontramos diferencias significativas en las puntuaciones de la escala y los niveles de melanina entre los grupos tratados y no tratados, y el grupo tratado con láser mostró mejores resultados. El láser high-fluence Q-switched Nd:YAG , sin aclarar la piel, demostró ser eficaz y seguro para tratar estas inusuales manchas mongoles.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
Estudiamos la eficacia y seguridad del uso de un tratamiento con láser específico para ABNOM y analizamos qué factores podrían afectar su eficacia. Analizamos a 110 pacientes que recibieron ABNOM y recibieron entre dos y nueve tratamientos con láser. Descubrimos que el tratamiento funcionó mejor cuanto más tiempo se realizó, pero no tan bien en pacientes de mayor edad. También funcionó mejor en pacientes con piel más clara (tipo III) y áreas afectadas más pequeñas (menos de 10 cm2) . Tener melasma junto con ABNOM hizo que el tratamiento fuera menos efectivo. El color o la cantidad de áreas afectadas no parecieron marcar la diferencia. Alrededor del 10% de los pacientes desarrollaron manchas más oscuras después del tratamiento. El tratamiento múltiple temprano dio buenos resultados. Los pacientes mayores con piel más oscura y manchas más oscuras tienen más probabilidades de tener manchas más oscuras después del tratamiento. Para los pacientes con ABNOM y melasma, es mejor utilizar un láser de menor energía para evitar que el melasma empeore.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
○ Tratamiento
Los agentes blanqueadores rara vez ayudan. A diferencia del melasma, ABNOM se puede mejorar con tratamiento con láser y dejar que se elimine sin recurrencia. El tratamiento con láser se puede realizar de 10 a 20 veces para tratar la ABNOM.
#QS1064 laser